| 國立臺灣大學 |
2007- |
CABLE ANNUAL REPORT 2007
|
Yen, Lee-Lan; Chang, Hsing-Yi; Chuang, Yi-Li; Lee, Szu-Hsien; Hsiao, Chuhsing; Wu, Wen-Chi; Wu, Chi-Chen |
| 淡江大學 |
2000-05-01 |
Cable Modem的新規範-DOCSIS新標準
|
李維聰 |
| 國立臺灣大學 |
2005 |
Cable Voltage Measurement using OKITAI and OLU Submarine Cables for Monitoring Ocean Transport
|
Koga, Momoki; Liu, Cho-Teng; Villanoy, Cesar; Taira, Keisuke |
| 臺大學術典藏 |
2019 |
Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC)
|
Yang P.-W.;Liu Y.-C.;Chang Y.-H.;Lin C.-C.;Huang P.-M.;Hua K.-T.;Jang-Ming Lee;Hsieh M.-S.; Yang P.-W.; Liu Y.-C.; Chang Y.-H.; Lin C.-C.; Huang P.-M.; Hua K.-T.; JANG-MING LEE; Hsieh M.-S. |
| 臺大學術典藏 |
2019 |
Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC)
|
Yang P.-W.;Liu Y.-C.;Chang Y.-H.;Lin C.-C.;Pei-Ming Huang;Hua K.-T.;Lee J.-M.;Hsieh M.-S.; Yang P.-W.; Liu Y.-C.; Chang Y.-H.; Lin C.-C.; PEI-MING HUANG; Hua K.-T.; Lee J.-M.; Hsieh M.-S. |
| 臺大學術典藏 |
2020-03-05T08:03:56Z |
Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC)
|
Yang P.-W.;Liu Y.-C.;Chang Y.-H.;Lin C.-C.;Huang P.-M.;Hua K.-T.;Lee J.-M.;Min-Shu Hsieh; Yang P.-W.; Liu Y.-C.; Chang Y.-H.; Lin C.-C.; Huang P.-M.; Hua K.-T.; Lee J.-M.; MIN-SHU HSIEH |
| 臺大學術典藏 |
2021-05-27T08:09:47Z |
Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC)
|
Yang P.-W.;Liu Y.-C.;Chang Y.-H.;Lin C.-C.;Huang P.-M.;Kuo-Tai Hua;Lee J.-M.;Hsieh M.-S.; Yang P.-W.; Liu Y.-C.; Chang Y.-H.; Lin C.-C.; Huang P.-M.; KUO-TAI HUA; Lee J.-M.; Hsieh M.-S. |
| 臺大學術典藏 |
2021-08-22T00:00:08Z |
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Brose, Marcia S.; Robinson, Bruce; Sherman, Steven I.; Krajewska, Jolanta; Chia-Chi Lin; Vaisman, Fernanda; Hoff, Ana O.; Hitre, Erika; Bowles, Daniel W.; Hernando, Jorge; Faoro, Leonardo; Banerjee, Kamalika; Oliver, Jennifer W.; Keam, Bhumsuk; Capdevila, Jaume |
| 臺大學術典藏 |
2022-09-15T01:08:47Z |
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Brose M.S.; Robinson B.; Sherman S.I.; Krajewska J.; Chia-Chi Lin; Vaisman F.; Hoff A.O.; Hitre E.; Bowles D.W.; Hernando J.; Faoro L.; Banerjee K.; Oliver J.W.; Keam B.; Capdevila J. |
| 臺大學術典藏 |
2021-08-31T06:29:16Z |
Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design
|
Kelley R.K.; W Oliver J.; Hazra S.; Benzaghou F.; Yau T.; ANN-LII CHENG; Rimassa L. |
